|
|
Vaccine Detail
|
Allogeneic Dendritic Cell Vaccine COMBIG-DC |
| Vaccine Information |
- Vaccine Name: Allogeneic Dendritic Cell Vaccine COMBIG-DC
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007220
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IFNG
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- TNF
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: (Procaccio et al., 2017)
- Description: A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells. (NCIT_C99902).
Patients newly diagnosed with metastatic renal cell carcinoma and hepatocellular carcinoma have received COMBIG-DC vaccinations in early stage clinical trials. NCT01525017, NCT01974661
|
| Host Response |
|
|
| References |
NCIT_C99902: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C99902]
Procaccio et al., 2017: Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S. Immunotherapy in Gastrointestinal Cancers. BioMed research international. 2017; 2017; 4346576. [PubMed: 28758114].
|
|
